These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
172 related items for PubMed ID: 11175665
41. Mimosine is a cell-specific antagonist of folate metabolism. Oppenheim EW, Nasrallah IM, Mastri MG, Stover PJ. J Biol Chem; 2000 Jun 23; 275(25):19268-74. PubMed ID: 10766749 [Abstract] [Full Text] [Related]
43. Mimosine arrests the cell cycle after cells enter S-phase. Hughes TA, Cook PR. Exp Cell Res; 1996 Feb 01; 222(2):275-80. PubMed ID: 8598214 [Abstract] [Full Text] [Related]
44. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. J Lab Clin Med; 2001 Aug 01; 138(2):130-8. PubMed ID: 11477380 [Abstract] [Full Text] [Related]
45. Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells. Simonart T, Boelaert JR, Mosselmans R, Andrei G, Noel JC, De Clercq E, Snoeck R. Gynecol Oncol; 2002 Apr 01; 85(1):95-102. PubMed ID: 11925126 [Abstract] [Full Text] [Related]
47. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1). Fernández-Martín JL, Menéndez-Fraga P, Canteros MA, Díaz-López JB, Cannata-Andía JB. Clin Chim Acta; 1994 Oct 31; 230(2):137-45. PubMed ID: 7834865 [Abstract] [Full Text] [Related]
48. Cell cycle arrest at the initiation step of human chromosomal DNA replication causes DNA damage. Szüts D, Krude T. J Cell Sci; 2004 Oct 01; 117(Pt 21):4897-908. PubMed ID: 15456844 [Abstract] [Full Text] [Related]
49. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells. Link G, Konijn AM, Hershko C. J Lab Clin Med; 1999 Feb 01; 133(2):179-88. PubMed ID: 9989770 [Abstract] [Full Text] [Related]
51. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals. Sheppard LN, Kontoghiorghes GJ. Arzneimittelforschung; 1993 Jun 01; 43(6):659-63. PubMed ID: 8352819 [Abstract] [Full Text] [Related]
52. Protective effect of iron chelators on epirubicin-induced fibroblast toxicity. Henriksson R, Grankvist K. Cancer Lett; 1988 Dec 15; 43(3):179-83. PubMed ID: 3144433 [Abstract] [Full Text] [Related]
56. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats. Emara AM, El Kelany RS, Moustafa KA. Hum Exp Toxicol; 2006 Jul 15; 25(7):375-85. PubMed ID: 16898166 [Abstract] [Full Text] [Related]